Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and Mobilization of Progenitor Cells in Peripheral Arterial Disease
This trial is active, not recruiting.
|Condition||peripheral arterial disease|
|Treatments||granulocyte-macrophage colony stimulating factor, placebo|
|Collaborator||National Institutes of Health (NIH)|
|Start date||September 2009|
|End date||January 2013|
|Trial size||180 participants|
|Trial identifier||NCT01041417, IRB00021976, NIH 1RC2HL101515-01|
Peripheral arterial disease is a common condition in older adults involving poor arterial circulation in the legs leading to leg pain and debility. The body's own circulating blood vessel stem cells may help to improve circulation. This study will test whether treatment with the drug granulocyte macrophage colony stimulating factor (GM-CSF) will improve symptoms and signs of peripheral arterial disease over placebo after four weeks of therapy. As well this study will examine whether improvements in blood vessel function can be observed. Finally, we will measure blood vessel function and stem cell levels in order to determine whether they can help to predict whether patients wither peripheral arterial disease will suffer further cardiovascular complications.
|Endpoint classification||safety/efficacy study|
|Intervention model||parallel assignment|
|Masking||double blind (subject, caregiver, investigator)|
To investigate whether GM-CSF will improve symptoms of claudication in patients with PAD, measured objectively as improvement in treadmill exercise tolerance.
time frame: 6 months
Change in exercise tolerance will be due to improvement in collateral blood flow measured by ankle-brachial index, transcutaneous oxygen concentration, and calf blood flow measured by MRI, and/or improvement in endothelial dysfunction.
time frame: 6 months
Male or female participants from 21 years up to 80 years old.
- 160 males or post-menopausal females between 21 and 80 years of age. Female subjects must be (a) post-menopausal, (b) surgically sterile or (c) use adequate birth control and have a negative pregnancy test within 3 days prior to administration of study drug and should not be breastfeeding.
- Documented PAD (By Ankle-Brachial Indices or Angiographically)
- Clinically stable (at least 2 months) history of intermittent claudication with no change in symptom severity in the 2 months prior to screening.
- On stable statin therapy for previous 3 months.
- Peak Walking Time (PWT) between 1 and 12 minutes on a standardized Gardner treadmill protocol.
- A Doppler-derived ankle-brachial index (ABI) of < 0.85 in the symptomatic limb after 10 minutes of rest at screening. For subjects with an ABI of >1.3 (non-compressible arteries) a Toe-Brachial Index (TBI) of < 0.70 must be obtained for subject qualification, or if ABI is > 0.85 to 1.0 , and a reduction of 20% in ABI measured within 1 minute of treadmill testing.
- On appropriate and stable medical therapy for atherosclerosis for at least 2 months.
- Able to give informed consent.
- Diabetics with a dilated eye exam excluding proliferative retinopathy in the previous 12 months.
- Recent or current active infections (treated with antibiotics).
- Recent (3 months) change in statin therapy
- Critical limb ischemia either chronic (category 3 and 4 of SVS classification) or acute ischemia manifested by rest pain, ulceration, or gangrene.
- Lower extremity vascular surgery, angioplasty or lumbar sympathectomy within 3 months of enrollment.
- Participation in a structured exercise treatment protocol within 3 months of enrollment.
- Prior myeloid cancer.
- Unstable angina, myocardial infarction, TIA, stroke or revascularization in the preceding 4 months.
- Severe heart failure (Class III or IV), heart muscle disease or atrial fibrillation.
- Limitation on exercise for symptoms other than intermittent claudication such as arthritis or dyspnea.
- Uncontrolled diabetes mellitus (defined as HbA1c > 10.0).
- Chronic renal disease (creatinine of >2.5 mg/dl) or hepatic disease (> 3 X elevations in AST and ALT).
- Ophthalmologic conditions associated with a neo-vascular response.
- Alcohol or drug abuse, or any other disease process that, in the opinion of the PI, will interfere with the ability of the patient to participate in the study.
|Official title||Granulocyte-Macrophage Stimulating Factor (GM-CSF) and Mobilization of Progenitor Cells in Peripheral Arterial Disease: A Phase II Randomized Study|
|Principal investigator||Arshed Quyyumi, MD|
Call for more information